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ABSTRACT Sarcopenia is a heterogeneous skeletal muscle disorder involving the loss of muscle mass
and function. However, the prevalence of sarcopenia based on the most recent definition remains to be
determined in older people with chronic airway diseases.
The aim was to evaluate sarcopenia prevalence and association with chronic airway diseases and its lung
function in an older population, using the European Working Group on Sarcopenia in Older People 2
(EWGSOP2) criteria.
We performed a cross-sectional analysis in 5082 participants (mean age 69.0±8.8 years, 56% females) from
the Rotterdam Study. Participants with interpretable spirometry and an available assessment of sarcopenia
were included. The appendicular skeletal muscle mass index (ASMI) and handgrip strength (HGS) were
assessed using dual-energy X-ray absorptiometry (DXA) and a hydraulic hand dynamometer, respectively.
We analysed the association between sarcopenia and chronic airway diseases by using regression models
adjusted for age, sex, smoking status, total fat percentage and other relevant confounders.
Participants with chronic airway diseases had higher prevalence of probable sarcopenia (12.0%, 95% CI
10.2–13.8) and confirmed sarcopenia (3.0%, 95% CI 2.1–3.9) than without. Chronic airway diseases were
associated with “probable sarcopenia” (OR 1.28, 95% CI 1.02–1.60), “confirmed sarcopenia” (OR 2.13,
95% CI 1.33–3.43), reduced HGS (β −0.51 (−0.90–−0.11)) and reduced ASMI (β −0.19 (−0.25–−0.14)).
Forced expiratory volume in 1 s <80% was associated with lower HGS (β −1.03 (−1.75–−0.31)) and lower
ASMI (β −0.25 (−0.36–−0.15)) than forced expiratory volume in 1 s ⩾80%.
Sarcopenia was prevalent and associated with chronic airway diseases among older population. These
results suggest the need for early diagnosis of sarcopenia in older people with chronic airway diseases by
applying EWGSOP2 recommendations.
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Changes in muscles undergo permanent shifts, particularly after the 5th decade of life, there is 1–2% loss of
muscle mass per year [1] and 1.5–5% loss of muscle strength [2]. This condition is called sarcopenia [3],
which affects around 10% of the healthy older population [4]. Nevertheless, sarcopenia is not only a
problem in older people, but it is also a consequence of chronic diseases [3]. Recently, the European
Working Group on Sarcopenia in Older People (EWGSOP2) has defined secondary sarcopenia as a
consequence of concomitant long-term conditions, such as chronic airway diseases (i.e. chronic obstructive
pulmonary disease (COPD)) [5].
Asthma, COPD and asthma–COPD overlap (ACO) are the leading chronic airway diseases that
encompass multiple clinical phenotypes and molecular endotypes with significant differences in clinical,
functional, imagining, prognosis and response to treatment [6, 7]. Around 30% of the global population
is affected by asthma during their lifetime [8], and 10% of the adult population has COPD [9, 10]. ACO
is a syndrome that affects between 9% and 55% of those with asthma or COPD [8]. Attention for these
chronic airway diseases is rising, given their increasing burden related to multiple extrapulmonary
manifestations which gradually contribute to disability [7, 11]. Notably, in COPD patients, the evidence is
emerging that sarcopenia affects functional capacity [11]. The prevalence of sarcopenia in COPD patients
has been reported to range widely, from 8% to 63%, depending on the adopted diagnostic method,
definition criteria and the population setting [12]. In the last decade, we have broadened our
understanding of the pathophysiology of primary sarcopenia in healthy older adults. In contrast, the
mechanisms leading to secondary sarcopenia (in patients with chronic health conditions) remain unclear;
mainly because there are multiples common features linked with both sarcopenia and COPD, such as
age, physical inactivity, weight loss, lung function, smoking, inflammatory cytokines and comorbidities,
among others [13–15].
Although the association between sarcopenia and COPD population has been reported in the past [16, 17],
there are no studies that have evaluated this association using the new consensus definition and cut-off
values recommended by EWGSOP2. Therefore, we aimed to provide an up-to-date estimate of the
prevalence of sarcopenia among older people with chronic airway diseases by applying the EWGSOP2
criteria. Our secondary objective was to determine the association between sarcopenia (probable and
confirmed) and its components (handgrip and appendicular skeletal muscle index), and chronic airway
diseases and lung function parameters.
Methods
Study design and participants
Our cross-sectional analysis was conducted within the Rotterdam Study, an ongoing prospective
population-based study, that investigates the occurrence and risk factors for chronic diseases in older
people [6, 18]. The details of the study objectives, design and main findings have been recently updated [6].
Briefly, the Rotterdam Study started in 1990 and has approximately 15000 participants enrolled in three
cycles (RSI, RSII and RSIII) from the Ommoord district, a well-defined suburb of the city of Rotterdam
(the Netherlands) [6]. Every 4–5 years, participants undergo a home interview and a visit to the research
centre for clinical examination and tests (e.g. spirometry). We included all participants with interpretable
spirometry and reliable measurements of handgrip strength (HGS) and lean mass by DXA, who visited the
research centre between 2009 and 2014 (Supplementary figure 1). Other relevant data in this study were
retrieved from medical records from the general practitioners and prescription data from pharmacies
serving the Ommoord area. The Rotterdam Study was approved by the medical ethics committee of the
Erasmus Medical Center, Rotterdam (registration number MEC 02.1015), and by the Dutch Ministry of
Health, Welfare and Sport (Population Screening Act WBO, license number 1071272-159521-PG). All
participants provided written informed consent.
Assessments
Assessment of chronic airways diseases
Trained paramedic personnel performed pre-bronchodilator spirometry using a Master Screen PTF Pro
spirometer (CareFusion, Houten, the Netherlands) according to the American Thoracic Society (ATS) and
the European Respiratory Society (ERS) guidelines [19]. Predicted values of forced expiratory volume
during in 1 s (FEV1) and forced vital capacity (FVC) were calculated using the reference equations
obtained from the Global Lung Function Initiative (GLI) which takes into account age, sex, height and
ethnicity [20]. Severity of obstruction in COPD was determined based on the modified Global Initiative
for Chronic Obstructive Lung Disease (GOLD) criteria: FEV1 ⩾80% predicted; without or mild airflow
limitation and FEV1 <80%predicted; moderate-to-severe airflow limitation [10]. The same cut-off values
were used to represent severity of obstruction in asthma and ACO cases.
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We considered participants diagnosed with chronic airways diseases before or at the time of DXA scan.
Chronic airway diseases included participants with asthma, COPD and ACO. COPD cases were identified
by spirometry data (FEV1/FVC ratio <0.7) and medical records. Asthma cases were defined based on
physician-diagnosed asthma, as evidenced in the medical records [21]. ACO cases were defined as
asthmatic participants who met the obstructive spirometry definition of COPD.
Participants who had restrictive spirometry or restrictive disease were classified as other lung diseases.
Participants who did not meet the definition of asthma or COPD because they had no clinical diagnosis
or normal spirometry (FEV1/FVC⩾0.7 and FVC⩾80%) at the time of the DXA scan date, were considered
as subjects without chronic airway diseases.
Assessment of sarcopenia
Sarcopenia status was defined using the EWGSOP2 criteria (table 1) [5]. Participants with low handgrip
were classified as having “probable sarcopenia”. Those with low handgrip and low lean mass were defined
as having “confirmed sarcopenia”. And those with “confirmed sarcopenia” plus low gait speed were
considered as having “severe sarcopenia”.
A single trained examinator performed handgrip test using a hydraulic hand dynamometer (Fabrication
Enterprises Inc., White Plains, NY, USA). Maximum HGS was obtained as the maximum value (kg) out of
three trials performed in the non-dominant hand [6]. Low HGS was defined as <27 kg for males and
<16 kg for females [5]. Lean mass was measured by DXA scan, using an iDXA total body-beam
densitometer (GE Lunar Corp, Madison, WI, USA). The scans were analysed with enCORE software
V13.6 providing measurements across pre-defined body regions of interest, namely the head, trunk, arms
and legs. The sum of the lean mass from the upper and lower limbs is called appendicular lean mass
(ALM). Appendicular skeletal muscle mass index (ASMI) was defined as ALM divided by the height
squared (m2). Low lean mass was classified as an ASMI of <7.0 kg·m−2 for males and <5.5 kg·m−2 for
females [5]. Another trained examinator measured gait speed during normal walk using the GAITRite
system (GAITRite Platinum; CIR Systems Inc., Sparta, NJ, USA) in a 5.79 m long electronic walkway with
1.27 cm wide pressure sensors [22]. Low gait speed was defined as ⩽0.8 m·s−1 for females and males [5].
Assessment of covariables
Body mass index (BMI) calculated as weight (kg) divided by height squared (kg·m−2) was used to classify
overweight (BMI 25–30 kg·m−2) and obesity (BMI ⩾30 kg·m−2). Age was categorised into two groups (<70
and ⩾70 years). Smoking status (never, past and current) was collected during home interviews. Total
body fat percentage was calculated as total body fat mass (kg) divided by body weight (kg) multiplied by
100. Physical activity was assessed by a validated adapted version of the Longitudinal Aging Study
Amsterdam (LASA) Physical Activity Questionnaire (LAPAQ) [23]and expressed in metabolic equivalent
of task (MET)-hours per week. Protein intake percentage was calculated using the formula: 4×protein
intake g)/daily total energy (kcal)×100. Participants who had no oral corticosteroid prescriptions
(Anatomical Therapeutic Chemical code (ATC): H02) before the DXA scan date were defined as never
users. Then we categorised users into current users when their last prescription was recorded ⩽90 days
before DXA scan, and past users when their last prescription was recorded >90 before DXA scan.
We identified four prevalent comorbid conditions before or at the time of DXA scan for each participant.
1) Type 2 diabetes (fasting plasma glucose level ⩾7 mmol·L−1, or a non-fasting plasma glucose level
⩾11.1 mmol·L−1 or the use of blood glucose-lowering medication) [24]; 2) hypertension (systolic blood
pressure ⩾160 mmHg or diastolic blood pressure ⩾100 mmHg or use of antihypertensive medication) [25];
TABLE 1 Definition of sarcopenia and cut-off values based on the revised and updated EWGSOP2 consensus
Definition Outcome Cut-off values
Male Female
Probable sarcopenia Low muscle strength: measured by hydraulic hand dynamometer <27 kg <16 kg
Sarcopenia Low muscle strength AND
Low lean mass: measured by DXA <7.0 kg·m−2 <5.5 kg·m−2
Severe sarcopenia Low muscle strength AND low lean mass AND
Low physical performance: measured by gait speed or ⩽0.8 m·s−1 ⩽0.8 m·s−1
Timed Up and Go Test ⩾20 s ⩾20 s
EWGSOP2: European Working Group of Sarcopenia in Older People 2; DXA: dual-energy X-ray absorptiometry.
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3) coronary heart disease (myocardial infarction, coronary artery bypass grafting (CABG) or percutaneous
coronary intervention (PCI) [26]; and 4) cancer (according to the International Classification of Diseases,
10th revision (ICD-10)) [27].
Statistical analyses
Descriptive characteristics were expressed as mean±SD or as median (interquartile range (IQR) and as
frequency (%). Data comparisons between participants with and without chronic airway diseases were
studied using t-test, Chi-squared test and multiple proportion Chi-squared test. Prevalence of sarcopenia
was calculated by dividing the total number of cases by the total number of participants and 95%
confidence intervals. Comparisons of sarcopenia status prevalence in these categories were tested using
Chi-squared tests.
Association between chronic airway diseases and sarcopenia status was examined by multinomial logistic
regression adjusted for previously identified confounders [13–15, 28, 29] such as age, sex, percentage of
fat, height and smoking. Linear regression models adjusted for the aforementioned confounders were used
to investigate the association between chronic airway diseases and the individual components of
sarcopenia. Moreover, in chronic airway diseases, we assessed the association between sarcopenia (and its
components) and FEV1 ⩾80% versus FEV1 <80% by using logistic and linear models adjusted for
confounders mentioned above. We did separate sensitivity analyses, including participants without
comorbidities and exploring the association between FEV1 (% predicted) and sarcopenia. Moreover, we
performed additional adjustments for FEV1/FVC, oral corticosteroids use, comorbidities, physical activity
and percentage of protein intake that might be either confounders or mediators.
For data missing more than 5%, we used the multiple imputation technique by chained equations. We
reported only pooled effect results in the regression models. P-values of less than 0.05 were considered
significant. All statistical analyses were performed using SPSS (IBM SPSS Statistics 24) and R version 3.6.0
(2019-04-26).
Results
Main characteristics of the study population
Among 7162 participants from the Rotterdam Study, 5306 had interpretable lung function and reliable
assessments of sarcopenia between 2009–2014. Of these, 224 participants were excluded due to other lung
diseases. Finally, 5082 participants (71.0%) were analysed in this study. 1246 participants had chronic
airway diseases, and 3836 had not (figure 1). Among these, 779 (62.5%) had COPD, 439 (35.2%) had
asthma, and 28 (2.3%) had ACO.
The mean±SD age of the study population was 69.0±8.8 years, and 56.3% (n=2863) of them were female.
Study population characteristics are presented in table 2.
Participants with chronic airway diseases were older, were significantly more often past or current smokers
(p<0.001), had lower lung function (p<0.001), lower handgrip strength (p<0.001), and were more
frequently oral corticosteroids users (p<0.001) than those without. Moreover, they presented with a higher
prevalence of comorbidities such as diabetes mellitus (16.8%), hypertension (75.5%) and coronary heart
diseases (11.9%) than without. Sarcopenia status stratified by the chronic airway diseases is described in
supplementary table 1.
Prevalence of “probable sarcopenia” and “confirmed sarcopenia”
The overall prevalence of sarcopenia (probable and confirmed) was 11.6% (95% CI 11.1–12.9) and
increased with age (supplementary figure 2) and number of comorbidities (supplementary table 2).
Participants older than 70 years had higher prevalence of probable sarcopenia (18.3% (95% CI 16.4–19.6))
and confirmed sarcopenia (3.0% (95% CI 2.2–3.7)) than younger than 70 years (3.5% (95% CI 3.3–4.7) and
0.5% (95% CI 0.2–0.7) respectively) (supplementary figure 2). Males had higher prevalence of confirmed
sarcopenia than females (2.0% (95% CI 1.4–2.6);1.0% (95% CI 0.6–1.4), respectively) (figure 2a). Ten
participants had severe sarcopenia (mean age 80.9±6.4 years) (supplementary table 3). To perform the
association analyses, these participants were included as confirmed sarcopenia status.
Participants with chronic airway diseases had higher prevalence of probable sarcopenia (12.0% (95% CI
10.2–13.8), 150 cases) and confirmed sarcopenia (3.0% (95% CI 2.1–3.9), 36 cases) (figure 2b) than those
without (9.3%, (95% CI 8.1–10.0) and 1.2% (95% CI 0.7–1.3) respectively). Prevalence of sarcopenia
among each chronic airway diseases (i.e. COPD, asthma) is described in supplementary table 4. Males
with chronic airway diseases had higher percentage of low handgrip and low ASMI than males without;
whereas, females had higher percentage of low ASMI compared to females without chronic airway diseases
(supplementary table 5).
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Association between chronic airways diseases and the prevalence of sarcopenia
Participants with chronic airways diseases had higher odds of having probable sarcopenia (1.28 (95% CI
1.02–1.60)) and two times higher odds to have confirmed sarcopenia (2.13 (95% CI 1.33–3.43)) than
participants without (table 3).
Association between chronic airway diseases and the components of sarcopenia: handgrip
strength and appendicular skeletal muscle index
Adjusted for age, sex, total body fat (%) and smoking, HGS (β −0.51 (−0.90, −0.11), p<0.001) and ASMI
(β −0.19 (−0.25, −0.14); p<0.001) were lower in participants with chronic airway diseases compared to
without (table 4).
Association between lung function and sarcopenia (and its components)
In participants with chronic airway diseases, FEV1 <80% was not significantly associated with sarcopenia
(probable and confirmed) (Supplementary table 6). FEV1 <80% was associated with lower HGS (β=−1.03
(−1.75; −0.31) and lower and ASMI (β=−0.25 (−0.36; −0.15)) compared with those who had FEV1 ⩾80%
(table 5).
Sensitivity analysis
When including only participants with no comorbidity (n=566), the prevalence of probable sarcopenia in
no chronic airway diseases decreased from 23.9% to 4.2%, and confirmed sarcopenia from 23.9% to 15.2%
(supplementary table 7). There were only a few cases for participants with confirmed sarcopenia.
Therefore, associations between sarcopenia and chronic airway diseases in this subgroup (without
Comorbidities n (%)
  No comorbidity  440 (11.5)
  One comorbidity  1542 (40.2)
  Two comorbidities  1306 (34.0)
  At least three comorbidities  548 (14.3)
Chronic airway diseases n (%)
  COPD 779 (62.5)
  Asthma  439 (35.2)
  ACO  28 (2.3)
3836 no chronic airway diseases 1246 chronic airways diseases
224 excluded:
  Other lung diseases
5082 participants for analysis
5306 participants with assessment of sarcopenia
580 excluded:
  418 no intepretable 
    spirometry tests
  162 no spirometry data
5886 participants with assessment of sarcopenia
7162 participants
1276 excluded:
 1220 no DXA
 56 no handgrip
FIGURE 1 Flow chart of the study population. DXA: dual-energy X-ray absorptiometry; ACO: Asthma and COPD
Overlap.
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comorbidities) were not possible. In the linear regression models, handgrip was not associated with
chronic airway diseases; whereas, appendicular skeletal muscle mass index remained associated
(supplementary table 8).
Regarding the spirometric parameters, among chronic airway diseases, FEV1 (% pred) was lower for all
sarcopenic persons (probable and confirmed) (supplementary figure 3). Associations between the









Subjects n 5082 3836 1246
Age years 69.0±8.8 68.6±8.5 70.1±9.1 <0.001
Age groups <0.001
<70 years 2873 (56.5) 2234 (58.2) 639 (51.3)
⩾70 years 2209 (43.5) 1602 (41.8) 607 (48.7)
Sex <0.001
Male 2219 (43.7) 1620 (42.2) 599 (48.1)
Female 2863 (56.3) 2216 (58.8) 647 (51.9)
BMI kg·m−2 27.5±4.2 27.5±4.1 27.2±4.4 0.061
Overweight 2446 (48.1) 1897 (49.4) 549 (44.1) <0.0029
Obese 1168 (23.0) 882 (23.0) 286 (22.9)
Smoking <0.05
Never 1717 (33.8) 1436 (37.4) 281 (22.5)
Past 2749 (54.1) 2041 (53.2) 708 (56.8)
Current 616 (12.1) 359 (9.4) 257 (20.6)
Lung function
FEV1/FVC % 76.0±7.7 78.8±4.6 67.5±8.9 <0.001
FVC predicted % 99.5±14.6 101.5±13.3 93.3±16.5 <0.001
FEV1 predicted % 98.5±17.8 103.7±13.9 82.5±19.1 <0.001
Total body fat %
Male 31.0±5.5 30.9±5.3 31.2±6.1 0.292
Female 40.1±6.1 40.1±6.0 39.9±6.5 0.595
HGS kg
Male 37.1±8.8 37.4±8.6 36.2±9.2 <0.05
Female 22.1±5.7 22.3±5.7 21.5±6.0 <0.05
ASMI kg·m−2
Male 8.3±0.9 8.4±0.9 8.0±0.9 <0.001
Female 6.9±0.9 6.9±0.8 6.8±0.9 <0.05
Walking speed# m·s−1 1.2 (1.1–1.3) 1.2 (1.1–1.4) 1.2 (1.1–1.3)
PA MET# h·week−2 42.6 (17.3–81.3) 44.5 (18.0–83.9) 36.8 (15.0–73.7)
Protein intake# % 15.7±2.9 15.7±2.8 15.5±3.0
OCS# <0.001
Never 3364 (66.2) 2749 (71.7) 615 (49.3)
Past 1592 (31.3) 1029 (26.8) 563 (45.2)
Current 126 (2.5) 58 (1.5) 68 (5.5)
Comorbidities
Type 2 diabetes 699 (13.8) 489 (12.7) 210 (16.8) <0.001
Hypertension 3656 (71.9) 2715 (70.8) 941 (75.5) <0.05
Cancer 524 (10.3) 389 (10.1) 135 (10.8) 0.484
CHD 434 (8.5) 286 (7.5) 148 (11.9) <0.001
Sarcopenia status
Probable sarcopenia 506 (10.0) 356 (9.3) 150 (12.0) <0.001
Confirmed
sarcopenia
82 (1.6) 46 (1.2) 36 (3.0)
Data are presented as mean±SD, n (%) or median (interquartile range), unless otherwise stated. BMI: body
mass index (overweight: BMI 25–30 kg·m−2, obese: BMI ⩾30 kg·m−2); FEV1/FVC: forced expiratory volume
in 1 s/forced vital capacity ratio; HGS: handgrip strength; ASMI: appendicular skeletal muscle mass index;
PA: physical activity; MET: metabolic equivalent of task; OCS: oral corticosteroids use; CHD: coronary
heart diseases. #: n (%) of missing values per variable. Walking speed: 1428 (28.1); physical activity: 601
(11.8); protein intake: 1041 (20.5); diabetes mellitus: 92 (1.8); hypertension: 1 (0.0); CHD: 53 (1.0). Original
data without imputations.
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components of sarcopenia and lung function in chronic airway disease participants are presented in
supplementary material figure 4 and table 9. HGS and ASMI were associated with FEV1 (% pred)
independent of sex, age, total body fat (%) and smoking status (β=0.04 (0.03; 0.07) and β =0.01 (0.01;
0.02) respectively). The associations between the spirometric parameters and the components of
sarcopenia are investigated for participants without chronic airway diseases in supplementary material
figure 4 and table 9.
Models with additional adjustment for lung function (FEV1/FVC), oral corticosteroids use, comorbidities,
physical activity and percentage of protein intake on the association between sarcopenia status and chronic
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FIGURE 2 Prevalence of probable sarcopenia and confirmed sarcopenia according to a) sex and b) the
presence or absence of chronic airway diseases.
TABLE 3 Association between chronic airway diseases and sarcopenia (EWGSOP2)
Sarcopenia status Chronic airway diseases Model 1 Model 2
OR (95% CI) OR (95% CI)
Probable sarcopenia (n=506) No (n=356) Ref. Ref.
Yes (n=150) 1.20 (0.96–1.49) 1.28 (1.02–1.60)
Confirmed sarcopenia (n=82) No (n=46) Ref. Ref.
Yes (n=36) 2.03 (1.29–3.21) 2.13 (1.33–3.43)
EWGSOP2: European Working Group of Sarcopenia in Older People 2; Ref.: no chronic airway diseases. Model
1 was adjusted for age and sex; model 2 was model 1 plus total body fat (%), height (cm) and smoking status.
TABLE 4 Association between chronic airway diseases and handgrip muscle strength (HGS) and appendicular skeletal muscle
index (ASMI)
Individual components of sarcopenia Chronic airway diseases Model 1 Model 2
β (SE) 95% CI β (SE) 95% CI
HGS kg# No (n=3836) Ref. Ref.
Yes (n=1246) −0.356 (0.203) −0.753−0.041 −0.506 (0.199) −0.898−−0.114
ASMI kg·m−2 No (n=3836) Ref. Ref.
Yes (n=1246) −0.209 (0.029) −0.265−−0.153 −0.190 (0.028) −0.245−−0.136
Ref.: no chronic airway diseases. Model 1 was adjusted for age and sex; model 2 was model 1 plus total body fat (%), height (cm) and smoking
status. #: height is only included in the HGS model due to ASMI already being calculated based on height (m2).
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Discussion
In this large population-based study of older people, the prevalence of probable sarcopenia (low handgrip)
was higher in participants with (12.0%) than without (9.3%) chronic airway diseases. Likewise, confirmed
sarcopenia (low handgrip and low lean mass) was higher in persons with chronic airway diseases (3.0%)
compared with those without (1.2%). Sarcopenia (probable and confirmed) was associated with chronic
airway disease independent of age, sex, total body fat, height and smoking status. Moreover, when
examining the individual components of sarcopenia, we demonstrated that older persons with chronic
airway diseases had both a lower appendicular lean mass index and lower handgrip than those without.
In our study, participants without chronic airway diseases had a similar prevalence of sarcopenia
(probable and confirmed) to the total global prevalence of 10% in the healthy older population [4].
However, for participants with chronic airway diseases, our prevalence estimates are slightly higher than
previous estimates among COPD subjects [16, 17]. One explanation for these estimate differences could be
that previous studies have reported prevalence of sarcopenia in COPD (range 7.9% to 8.4%) using the first
EWGSOP1 consensus [30]. Clinical studies have found similar effects in the association between
sarcopenia and COPD, but differed in their definition for sarcopenia and cut off values [12]. The updated
EWGSOP2 criteria incorporate changes, both conceptually and relating to the diagnostic algorithm [5].
For instance, cut-off values for handgrip and muscle mass were reset, and the central role of gait speed in
diagnosing sarcopenia is to discriminate the severity [5]. Therefore, the prevalence of sarcopenia in COPD
patients might have been underestimated in the previous studies.
We add to existing knowledge by reporting the prevalence of sarcopenia and its association with chronic
airway diseases by using the updated EWGSOP2 criteria [5]and by examining its association with lung
function. Additionally, the prevalence of sarcopenia (probable and confirmed) in asthma, COPD and
ACO, were similar; hence, we combined and redefined them as chronic airway diseases.
The pathophysiology of secondary sarcopenia is not fully understood. However, similar to primary
sarcopenia, it seems that inflammatory processes may lead to metabolic changes, which drive to an
TABLE 5 Association between FEV1 (⩾80% and <80%) and the components of sarcopenia in participants with chronic airway
diseases (n=1246)
Components of sarcopenia FEV1 % pred. Model 1 Model 2
β (SE) 95% CI β (SE) 95% CI
HGS kg# ⩾80% (n=725) Ref. Ref.
<80% (n=521) −1.246 (0.373) −1.978−−0.514 −1.03 (0.368) −1.749−−0.307
ASMI kg·m−2 ⩾80% (n=725) Ref. Ref.
<80% (n=521) −0.245 (0.054) −0.351−−0.139 −0.252 (0.053) −0.356−−0.148
FEV1: forced expiratory volume in 1 s; HGS: handgrip strength; ASMI: appendicular skeletal muscle mass index. Model 1 was adjusted for age
and sex; model 2 was model 1 plus total body fat (%), height and smoking status. #: height is only included in the HGS model due to ASMI
already being calculated based on height (m2).
TABLE 6 Odds ratio for chronic airway diseases according to sarcopenia status (EWGSOP2)
Probable sarcopenia Confirmed sarcopenia
OR (95% CI) OR (95% CI)
No additional adjustment 1.28 (1.02–1.60) 2.13 (1.33–3.43)
Additionally, adjusted for
FEV1/FVC 1.33 (1.01–1.77) 1.40 (0.73–2.66)
Oral corticosteroids use 1.16 (0.92–1.46) 1.94 (1.18–3.16)
Number of comorbidities 1.25 (1.00–1.56) 2.08 (1.29–3.35)
Physical activity# 1.27 (1.01–1.58) 2.07 (1.29–3.33)
Protein intake %# 1.28 (1.02–1.60) 2.15 (1.33–3.45)
EWGSOP2: European Working Group of Sarcopenia in Older People 2; FEV1/FVC: forced expiratory volume
in 1 s/forced vital capacity ratio. All odds are adjusted for age, sex, height, % total body fat and smoking
status. #: based on imputed data, n (%) of missing values: physical activity: 601 (11.8 protein intake: 1041
(20.5).
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imbalance between anabolic and catabolic mechanisms. Systemic inflammatory markers, such as
interleukin 6 and tumour necrosis factor (TNF)-α, C-reactive protein, increase catabolism. BYUN et al. [13]
found that high sensitivity TNFα (hsTNFα) correlates with sarcopenia in COPD patients. Indeed, patients
with COPD and older asthmatics present with a high-serum level of pro-inflammatory biomarkers [31].
However, for asthma, the underlying role of systemic inflammatory biomarkers in sarcopenia remains yet
unknown. Although ageing is another key factor that impacts muscle health, it is not clear whether these
changes are associated with chronic airway diseases or are purely due to age. In line with previous
studies [15], we observed an increased age-related prevalence of sarcopenia, particularly in those older
than 70 years. From our study population (mean age 69.0±8.8 years) we can expect an overlap between
primary and secondary sarcopenia (in asthma, COPD and ACO). However, in COPD patients, sarcopenia
seems to be more disease related than age related. Because muscle dysfunction in COPD is characterised
by a shift from type I to type II fibres [32]; whereas, age-related sarcopenia is mainly attributed to muscle
denervation and loss of type II fibres which are replaced by adipose tissue [33]. Therefore, these
differences indicate that other pathological mechanisms are involved in sarcopenia in COPD, and not
explained solely by advanced age. Nevertheless, in asthma patients, the mechanism of primary and
secondary sarcopenia is unknown. Consequently, additional longitudinal studies are necessary to further
investigate age-related changes in muscle health among persons with chronic airway diseases (i.e. asthma
and COPD).
We found that males had slightly higher prevalence of confirmed sarcopenia than females, similar to the
sex differences reported previously [34, 35]; however, these previous studies focussed only on lean mass
prevalence rather than sarcopenia. We showed that the overall prevalence of sarcopenia increased with an
increased number of comorbidities. For instance, the total prevalence of probable sarcopenia (10.0%) can
be attributed to a high average of total body fat (%) in female (40.1±6.1) and male (31.0±5.5). Long-term
exposure to the fat gain is associated with lower handgrip in older obese [36], and it is known to be one of
the essential causes of insulin resistance (another mechanism underlying sarcopenia) [37]. We performed
additional adjustment for comorbidities, oral corticosteroids use, physical activity and protein intake;
however, all of them had small effects on the magnitude of the estimates. In our study, chronic airway
diseases participants with FEV1 <80% had lower HGS and lower ASMI compared with FEV1 ⩾80%. These
results are consistent with the fact that, in COPD patients, the impairment in lung function affects diverse
systems that finally compromise functionality [38].
The strengths of our study are its population-based setting, robust assessment of chronic airway diseases
and high-quality information for the diagnosis of sarcopenia (i.e. DXA scan and handgrip). Limitations
should be considered when interpreting these results. Firstly, while EWGSOP2 employs the SARC-F
questionnaire for case-finding (supplementary 10), we did not use it [39]. Nevertheless, all participants in
our study had a measurement of handgrip and DXA scan. Secondly, for the present analysis, we would
expect a selection bias due to missing data for walking speed (28.1%). Mainly because older and severely ill
participants could not participate. However, only 2.2% (32 cases) correspond to the confirmed cases of
sarcopenia. Thirdly, as EWGSOP2 does not consider the clinical subgroup with decreased lean mass,
normal handgrip and low gait speed as being “sarcopenic”, we could have an “unclassified” group.
Particularly, in the assessment of COPD patients, who per se have muscle dysfunction, which affects
walking speed. Finally, despite the large sample size of the overall population, some subgroup analyses
included small numbers (e.g. age group differences (those <70 years with confirmed sarcopenia: n=13); no
comorbidity (those with confirmed sarcopenia: n=7)).
In summary, according to the EWGSOP2 recommendations, among older population, probable and
confirmed sarcopenia is more prevalent in participants with chronic airway diseases compared with those
without. Given the high prevalence of sarcopenia in older people with chronic airway diseases, could be
essential routinely screen for handgrip because a diagnosis of “probable sarcopenia” provides an important
opportunity for prompt intervention.
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